Bharat Biotech said the “comprehensive” study has demonstrated multiple benefits of its vaccine, including long-term immune response, cell-mediated immunity, safety of booster dose, and immunogenicity against the spike protein, N protein and neutralising antibody responses against alpha, beta, delta, delta plus and omicron variants.